Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Hasılat
551
594
560
625
490
390
Hasılat Artışı (YoY)
21%
6%
-10%
28%
26%
43%
Satınalma Maliyeti
266
322
289
321
207
134
Brüt Kâr
285
272
270
304
282
255
Satış, Genel ve İdari
97
209
191
351
303
197
Araştırma ve Geliştirme
-151
53
52
390
358
263
İşletme Giderleri
-51
380
109
735
804
462
Diğer Finansman Gelirleri (Giderleri)
-8
-4
-3
-1
0
-4
Kâr Öncesi Gelir
34
-170
168
-431
-517
-281
Kira Vergisi Gideri
17
2
6
-3
0
0
Net Kâr
3,111
2,961
-95
-226
-358
-204
Net Income Growth
Kâr Artışı
-1,857.99%
-3,217%
-57.99%
-37%
75%
112.99%
Dolaşım Daki Hisse Senetleri (Dilüte Edilmiş)
2,154.85
2,121.28
2,109.36
2,104.12
2,039.2
1,900.78
Hisse Değişimi (Yıllık Üst Üste)
2%
1%
0%
3%
7%
2%
EPS (Diluted)
1.44
1.39
-0.04
-0.1
-0.17
-0.1
EPS Artışı
-1,900%
-3,575%
-63%
-39%
63%
107%
Öz sermaye akışı
141
-72
-444
-323
-274
-278
Hisse Başı Öz Kaynak Akışı
--
--
--
--
--
--
Brüt Karşılık
51.72%
45.79%
48.21%
48.64%
57.55%
65.38%
Faaliyet Kâr Marjı
60.98%
-18.18%
28.57%
-68.96%
-106.53%
-52.82%
Kâr Marjı
564.6%
498.48%
-16.96%
-36.16%
-73.06%
-52.3%
Özsermaye Karlılık Oranı
25.58%
-12.12%
-79.28%
-51.68%
-55.91%
-71.28%
EBITDA
408
-31
233
-367
-475
-174
EBITDA Marjinali
74.04%
-5.21%
41.6%
-58.72%
-96.93%
-44.61%
D&A EBITDA için
72
77
73
64
47
32
Faaliyet Kârı
336
-108
160
-431
-522
-206
Faaliyet Kâr Marjı
60.98%
-18.18%
28.57%
-68.96%
-106.53%
-52.82%
Verilen Vergi Oranı
50%
-1.17%
3.57%
0.69%
0%
0%
Önemli İstatistikler
Önceki Kapanış
$1.77
Açılış fiyatı
$1.55
Günün Aralığı
$1.55 - $1.55
52 haftalık aralık
$1.24 - $2.42
İşlem hacmi
3.6K
Ort.Hacim
513
EPS (TTM)
-0.04
Dividend yield
--
Piyasa Değeri
$3.3B
Genscript Biotech Corp nedir?
Genscript Biotech Corp. is a holding company, which engages in the manufacture and sale of life sciences research products and services. The company is headquartered in Nanjing, Jiangsu and currently employs 5,769 full-time employees. The company went IPO on 2015-12-30. The firm operates its businesses through five segments. The Life-science Services and Products segment provides comprehensive research services and products. The Biologics Development Services segment provides comprehensive services to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene, cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment provides industrial enzyme development and production through non-pathogenic microbial strains constructed using genetic engineering. The Cell Therapy segment discovers and develops CAR-T therapies for the treatment of liquid and solid tumors. The Operation segment provides shared services to other segments. The firm mainly operates its businesses in the domestic and overseas markets.